Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.56 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 3.91 | 0.00 | 0.00 | 0.00 | 1.83 | 1.21 | 1.11 | 0.66 | 2.53 | 0.94 | 1.46 | 1.12 | 2.36 |
| — | -99.9% | -100.0% | -99.8% | -27.8% | +28.1% | -24.2% | -41.4% | +7.3% | -55.7% | -34.3% | -45.3% | -22.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -354.5% | -57.6% | -81.7% | -108.5% | -100.7% | -69.5% | -40.4% | -39.3% | -39.6% | -25.5% | -27.1% | -45.7% | -105.3% |
| — | +17.1% | -102.2% | -176.1% | -154.6% | -172.4% | -49.2% | +13.9% | +62.4% | +21.0% | -13.5% | -244.8% | -771.5% | |
| ROA | -262.9% | -43.6% | -60.6% | -70.5% | -66.8% | -54.0% | -34.3% | -34.7% | -34.7% | -22.9% | -23.2% | -38.2% | -95.6% |
| — | +19.2% | -76.5% | -103.4% | -92.6% | -135.5% | -47.9% | +9.3% | +63.7% | +23.4% | -3.2% | -200.5% | -733.0% | |
| ROIC | -1786.5% | — | — | -339.6% | -272.7% | -343.0% | -685.1% | -785.0% | -406.1% | -282.1% | -1429.0% | -762.4% | -203.5% |
| — | — | — | +56.7% | +32.9% | -21.6% | +52.1% | -3.0% | -99.5% | -411.8% | -3021.6% | -2727.8% | -596.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 5.2% YoY to 3.76x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | — | 0.00 | 0.01 | 0.04 | 0.03 | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 |
| — | — | -78.8% | -10.9% | +43.6% | +8.8% | -5.5% | -23.9% | -1.7% | +66.4% | +1243.4% | +772.9% | +897.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.22 | 3.76 | 3.45 | 2.93 | 1.22 | 3.97 | 4.82 | 9.70 | 7.71 | 9.57 | 12.05 | 5.65 | 8.40 |
| — | -5.2% | -28.4% | -69.8% | -84.1% | -58.5% | -60.0% | +71.5% | -8.2% | +4.9% | +35.6% | -63.5% | -55.5% | |
| Quick Ratio | 1.22 | 3.76 | 3.45 | 2.93 | 1.22 | 3.97 | 4.82 | 9.70 | 7.71 | 9.57 | 12.05 | 5.65 | 8.40 |
| — | -5.2% | -28.4% | -69.8% | -84.1% | -58.5% | -60.0% | +71.5% | -8.2% | +4.9% | +35.6% | -63.5% | -55.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonProcessa Pharmaceuticals, Inc.'s current P/E is -0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Processa Pharmaceuticals, Inc.'s business trajectory between earnings reports.